

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



2



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : <b>C07D 405/14, A61K 31/415, 31/42, 31/34, C07D 413/14, 417/14, 521/00</b>	A1	(11) International Publication Number: <b>WO 96/33194</b> (43) International Publication Date: <b>24 October 1996 (24.10.96)</b>
(21) International Application Number: <b>PCT/EP96/01606</b>		(74) Agent: <b>GRÜNECKER, KINKELDEY, STOCKMAIR &amp; SCHWANHÄUSSER; Maximilianstrasse 58, D-80538 München (DE).</b>
(22) International Filing Date: <b>17 April 1996 (17.04.96)</b>		
(30) Priority Data: <b>0460/95 21 April 1995 (21.04.95)</b>	DK	(81) Designated States: <b>AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).</b>
(71) Applicants (for all designated States except US): <b>NEUROSEARCH A/S [DK/DK]; Smedeland 26B, DK-2600 Glostrup (DK). MEIJI SEIKA KAISHA, LTD. [JP/JP]; Pharmaceutical Division, 4-16, Kyobashi 2-chome, Chuo-ku, Tokyo 104 (JP).</b>		
(72) Inventors; and		
(75) Inventors/Applicants (for US only): <b>TEUBER, Lene [DK/DK]; Anemonevej 32, DK-3500 Værløse (DK). WÄTJEN, Frank [DK/DK]; Afalder 22, DK-2730 Herlev (DK). FUKUDA, Yoshimasa [JP/JP]; Meiji Seika Kaisha, Ltd., Pharmaceutical Research Center, 760, Morooka-cho, Kohoku-ku, Yokohama 222 (JP). USHIRODA, Osamu [JP/JP]; Meiji Seika Kaisha, Ltd., Pharmaceutical Research Center, 760, Morooka-cho, Kohoku-ku, Yokohama 222 (JP). SASAKI, Toshiro [JP/JP]; Meiji Seika Kaisha, Ltd., Pharmaceutical Research Center, 760, Morooka-cho, Kohoku-ku, Yokohama 222 (JP).</b>		

(54) Title: BENZIMIDAZOLE COMPOUNDS AND THEIR USE AS MODULATORS OF THE GABA A RECEPTOR COMPLEX

(57) Abstract

The present patent application discloses compounds having formula (I) or a pharmaceutically acceptable salt thereof or an oxide thereof, wherein R<sup>3</sup> is (II), wherein A, B and D each is CH, or one or two of A, B and D is N and the others are CH; R<sup>11</sup> is phenyl, benzimidazolyl, or monocyclic heteroaryl all of which may be substituted one or more times with substituents selected from alkyl, alkoxy, phenyl, halogen, CF<sub>3</sub>, amino, nitro, cyano, acyl, acylamino, phenyl and monocyclic heteroaryl; and one of R<sup>6</sup> and R<sup>7</sup> is hydrogen and the other is furanyl or isoxazolyl each of which may be substituted one or more times with substituents selected from halogen, alkyl, alkoxy and phenyl. The compounds are useful for the treatment of various central nervous system disorders such as epilepsy and other convulsive disorders, anxiety, sleep disorders and memory disorders.



**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Larvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

**BENZIMIDAZOLE COMPOUNDS AND THEIR USE AS MODULATORS OF THE GABA A RECEPTOR COMPLEX**

- 5 This invention relates to novel benzimidazole compounds, pharmaceutical compositions containing these compounds, methods of treating therewith, and to method of preparing such benzimidazole compounds. The novel compounds are useful in the treatment of central nervous system diseases and disorders, which are responsive to modulation of the GABA<sub>A</sub> receptor complex, such as for example anxiety, sleep disorders, memory 10 disorders, and epilepsy or other convulsive disorders,

**Background of the Invention**

Receptors for  $\gamma$ -aminobutyric acid (GABA), GABA<sub>A</sub> receptors are the most abundant 15 inhibitory receptors in mammalian brain. The GABA<sub>A</sub> receptor are structurally constituted as macromolecular heteropentameric assemblies (combinations of  $\alpha$ ,  $\beta$ , and  $\gamma/\delta$  protein subunits). Several subtypes of such GABA<sub>A</sub> receptors have been described by techniques of modern molecular biology.

Each GABA<sub>A</sub> receptor complex comprises a chloride ion channel that controls chloride 20 flux across the neuronal membrane, and multiple recognition sites for small modulatory molecules such as benzodiazepines, barbiturates, picrotoxin, and certain steroids. When GABA interacts with its receptor, the ion channel is opened, chloride influx is enhanced, the membrane is hyperpolarized and the cell becomes less responsive to excitatory stimuli. This GABA induced ion current can be regulated by diverse agents, 25 including agents that interact with the benzodiazepine receptor or recognition site.

Agents that bind or interact with the modulatory sites on the GABA<sub>A</sub> receptor complex, such as for example the benzodiazepine receptor, can have either enhancing effect on the action of GABA, i.e. a positive modulatory effect of the receptor (agonists, partial 30 agonists), an attenuating effect on the action of GABA, i.e. negative modulation of the receptor (inverse agonists, partial inverse agonists), or they can block the effect of both agonists and inverse agonists by competitive block (antagonists or ligands without intrinsic activity).

Agonists generally produce muscle relaxant, hypnotic, sedative, anxiolytic, and/or anticonvulsant effects, while inverse agonists produce proconvulsant, anti-inebriant, and anxiogenic effects. Partial agonists are characterized as compounds with anxiolytic effects but without or with reduced muscle relaxant, hypnotic and sedative

5 effects, whereas partial inverse agonists are considered to be useful as cognition enhancers.

- Numerous compounds belonging to different series of compounds having affinity for the benzodiazepine receptors have been synthesized during the last three decades.
- 10 However, although the benzodiazepine receptor sites are still considered as very attractive biological sites for interfering with the CNS to treat various disorders and diseases, then nearly all previously synthesized compounds acting at these receptor sites have failed during clinical development because of unacceptable side effects.
- 15 The present invention provides novel benzimidazole compounds that interact with the benzodiazepine receptor of the GABA<sub>A</sub> receptor complex. The compounds of the present invention are valuable modulators of the GABA<sub>A</sub> receptor complex.

#### Object of the invention

20

It is an object of the present invention to provide novel benzimidazole compounds and pharmaceutically acceptable acid addition salts thereof, which are useful in the treatment of central nervous system disorders, diseases or ailments, which are responsive to the modulation of the GABA<sub>A</sub> receptor complex, and especially the

25 positive modulation of the GABA<sub>A</sub> receptor complex.

Another object of the present invention is to provide pharmaceutical compositions comprising the novel benzimidazole compounds being useful for the above purposes. Still another object of the present invention is to provide a novel method of treating with

30 the novel benzimidazole compounds.

A further object of the present invention is to provide a method of preparing the novel pharmaceutical compositions.

Additional objects will be obvious from the following description, and others will be obvious to one skilled in the art.


### Summary of the Invention

5

The invention then, inter alia, comprises the following, alone or in combination:

A compound having the formula:


10



or a pharmaceutically acceptable salt thereof or an oxide thereof  
wherein

15

$R^3$  is



wherein

20      A, B and D each is CH, or one or two of A, B and D is N and the others are CH;

$R^{11}$  is phenyl, benzimidazolyl, or monocyclic heteroaryl all of which may be substituted one or more times with substituents selected from alkyl, alkoxy, phenyl, halogen,  $CF_3$ , amino, nitro, cyano, acyl, acylamino, phenyl and monocyclic heteroaryl; and

25      one of  $R^6$  and  $R^7$  is hydrogen and the other is furanyl or isoxazolyl each of which may be substituted one or more times with substituents selected from halogen, alkyl, alkoxy and phenyl;

a compound as above, which is

1-(3-(1-imidazolyl)phenyl)-5-(3-furanyl)benzimidazole,  
1-(3-(2-methyl-1-imidazolyl)phenyl)-5-(3-furanyl)benzimidazole, or  
1-(3-(5-pyrimidinyl)phenyl)-5-(3-furanyl)benzimidazole, or a pharmaceutically  
acceptable salt thereof or an oxide thereof;

5

a pharmaceutical composition comprising an effective amount of a compound as any  
above, or a pharmaceutically-acceptable addition salt thereof or an oxide thereof,  
together with at least one pharmaceutically-acceptable carrier or diluent;

10 the use of a compound as any above for the preparation of a medicament for the  
treatment of a disorder or disease of a living animal body, including a human, which  
disorder or disease is responsive to modulation of the GABA<sub>A</sub> receptor complex of the  
central nervous system;

15 the use of a compound as any above for the preparation of a medicament for the  
treatment of a disorder or disease of a living animal body, including a human, which  
disorder or disease is responsive to positive modulation of the GABA<sub>A</sub> receptor  
complex of the central nervous system;

20 the use of a compound as any above for the preparation of a medicament for the  
treatment of a disorder or disease selected from anxiety, sleep disorders, memory  
disorders, epilepsy and any other convulsive disorder;

25 a method of treating a disorder or disease of a living animal body, including a human,  
which disorder or disease is responsive to modulation of the GABA<sub>A</sub> receptor complex  
of the central nervous system comprising administering to such a living animal body,  
including a human, in need thereof a therapeutically-effective amount of a compound  
as any above.

30 the method above, wherein a disorder or disease responsive to the positive modulation  
of the GABA<sub>A</sub> receptor complex is treated;

the method above, wherein anxiety, sleep disorders, memory disorders, epilepsy or  
any other convulsive disorder is treated; and

the method above, wherein the active ingredient is administered in form of a pharmaceutical composition thereof, in which it is present together with a pharmaceutically-acceptable carrier or diluent.

Halogen is fluorine, chlorine, bromine, or iodine.

5

Alkyl means a straight chain or branched chain of from one to eight carbon atoms or cyclic alkyl of from three to seven carbon atoms, including but not limited to, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl; methyl, ethyl, propyl, isopropyl and t-butyl are preferred groups.

10

Alkoxy means -O-alkyl, wherein alkyl is as defined above.

Acy means -(C=O)-H or -(C=O)-alkyl, wherein alkyl is as defined above.

15

Acylamino is acyl-NH- wherein acyl is as defined above.

Amino is -NH<sub>2</sub> or -NH-alkyl or -N-(alkyl)<sub>2</sub>, wherein alkyl is as defined above.

20

Monocyclic heteroaryl is a 5- or 6-membered heterocyclic monocyclic group. Such a monocyclic heteroaryl group includes, for example, oxazol-2-yl, oxazol-4-yl, oxazol-5-yl, isoxazol-3-yl, isoxazol-4-yl, isoxazol-5-yl, thiazol-2-yl, thiazol-4-yl, thiazol-5-yl, isothiazol-3-yl, isothiazol-4-yl, isothiazol-5-yl, 1,2,4-oxadiazol-3-yl, 1,2,4-oxadiazol-5-yl, 1,2,4-thiadiazol-3-yl, 1,2,4-thiadiazol-5-yl, 1,2,5-oxadiazol-3-yl, 1,2,5-oxadiazol-4-yl,

25

1,2,5-thiadiazol-3-yl, 1,2,5-thiadiazol-4-yl, 1-imidazolyl, 2-imidazolyl, 4-imidazolyl, 1-pyrrolyl, 2-pyrrolyl, 3-pyrrolyl, 2-furanyl, 3-furanyl, 2-thienyl, 3-thienyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrimidyl, 4-pyrimidyl, 5-pyrimidyl, 3-pyridazinyl, 4-pyridazinyl, 2-pyrazinyl, 1-pyrazolyl, 3-pyrazolyl, and 4-pyrazolyl.

30

Examples of pharmaceutically-acceptable addition salts include inorganic and organic acid addition salts such as the hydrochloride, hydrobromide, phosphate, nitrate, perchlorate, sulphate, citrate, lactate, tartrate, maleate, fumarate, mandelate, benzoate, ascorbate, cinnamate, benzenesulfonate, methanesulfonate, stearate, succinate, glutamate, glycollate, toluene-p-sulphonate, formate, malonate, naphthalene-2-sulphonate, salicylate and the acetate for example.

35

Other acids such as oxalic acid, while not in themselves pharmaceutically acceptable may be useful in the preparation of salts useful as intermediates in obtaining compounds of the invention and their pharmaceutically acceptable acid addition salts.

- 5 Such salts are formed by procedures well known in the art.

Further, the compounds of this invention may exist in unsolvated as well as in solvated forms with pharmaceutically acceptable solvents such as water, ethanol and the like. In general, the solvated forms are considered equivalent to the unsolvated forms for the 10 purposes of this invention.

Some of the compounds of the present invention exist in (+) and (-) forms as well as in racemic forms. Racemic forms can be resolved into the optical antipodes by known methods, for example, by separation of diastereomeric salts thereof, with an optically 15 active acid, and liberating the optically active amine compound by treatment with a base. Another method for resolving racemates into the optical antipodes is based upon chromatography on an optical active matrix. Racemic compounds of the present invention can thus be resolved into their optical antipodes, e.g., by fractional crystallization of d- or l- (tartrates, mandelates, or camphorsulphonate) salts for 20 example. The compounds of the instant invention may also be resolved by the formation of diastereomeric amides by reaction of the compounds of the present invention with an optically active activated carboxylic acid such as that derived from (+) or (-) phenylalanine, (+) or (-) phenylglycine, (+) or (-) camphanic acid or by the formation of diastereomeric carbamates by reaction of the compounds of the present 25 invention with an optically active chloroformate or the like.

Additional methods for the resolution of optical isomers, known to those skilled in the art may be used, and will be apparent to the average skilled in the art. Such methods include those discussed by J. Jaques, A. Collet, and S. Wilen in "Enantiomers, 30 Racemates, and Resolutions", John Wiley and Sons, New York (1981).

The compounds of the invention may be prepared in numerous ways.

The compounds of the invention and their pharmaceutically acceptable derivatives may thus be prepared by any method known in the art for the preparation of compounds of analogous structure and as shown in the representative examples which follows.

- 5 Figures 1-6 describe methods for the preparation of compounds of the invention wherein R<sup>6</sup> is furanyl or isoxazolyl and R<sup>7</sup> is hydrogen. Compounds of the invention wherein R<sup>7</sup> is furanyl or isoxazolyl and R<sup>6</sup> is hydrogen can be synthesized analogously.

Starting materials for the processes described in the present patent application are  
10 known or can be prepared by known processes from commercially available chemicals.

The products of the reactions described herein are isolated by conventional means such as extraction, crystallization, distillation, chromatography and the like.

15

### Biology

4-aminobutyric acid (GABA) is the major inhibitory neurotransmitter and has been shown to act throughout both the central and peripheral nervous system. At present  
20 two types of GABA receptors are known, the GABA<sub>A</sub> and the GABA<sub>B</sub> receptors. Recent molecular biology has demonstrated that the GABA<sub>A</sub> receptors can be subdivided into numerous subreceptors consistant with the selective and or partial pharmacological effects observed with certain benzodiazepine receptor ligands as opposed to the unselective effects observed for the classical benzodiazepine receptor ligands such as  
25 for example diazepam. Activation of GABA receptors leads to alterations in membrane potential (hyperpolarization). The GABA<sub>A</sub> receptors are associated with chloride influx through its associated and integrated chloride channel, whereas GABA<sub>B</sub> receptor activation indirectly alters potassium and calcium channels as well as modifies second messenger production. The GABA<sub>A</sub> recognition sites can be activated by  
30 GABA, muscimol; and isoguvacine for example, but not by GABA<sub>B</sub> agonists such as for example baclofen. The modulatory GABA<sub>A</sub> recognition site at the benzodiazepine receptor sites can be selectively radiolabelled with <sup>3</sup>H-flunitrazepam. The affinity of various potential ligands for the benzodiazepine receptor sites can thus be evaluated by estimating the ability of test compounds to displace <sup>3</sup>H-flunitrazepam.

35

**Method**

Tissue Preparation: Preparations are performed at 0-4°C unless otherwise indicated. Cerebral cortex from male Wistar rats (150-200 g) is homogenized for 5-10 sec in 20 ml Tris-HCl (30 mM, pH 7.4) using an Ultra-Turrax homogenizer. The suspension is centrifuged at 27,000 x g for 15 min and the pellet is washed three times with buffer (centrifuged at 27,000 x g for 10 min). The washed pellet is homogenized in 20 ml of buffer and incubated on a water bath (37°C) for 30 min to remove endogenous GABA and then centrifuged for 10 min at 27,000 x g. The pellet is then homogenized in buffer and centrifuged for 10 min at 27,000 x g. The final pellet is resuspended in 30 ml buffer and the preparation is frozen and stored at -20°C.

Assay: The membrane preparation is thawed and centrifuged at 2°C for 10 min at 27,000 x g. The pellet is washed twice with 20 ml 50 mM Tris-citrate, pH 7.1 using an Ultra-Turrax homogenizer and centrifuged for 10 min at 27,000 x g. The final pellet is resuspended in 50 mM Tris-citrate, pH 7.1 (500 ml buffer per g of original tissue), and then used for binding assays. Aliquots of 0.5 ml tissue are added to 25 µl of test solution and 25 µl of <sup>3</sup>H-FNM (1 nM, final concentration), mixed and incubated for 40 min at 2°C. Non-specific binding is determined using clonazepam (1 µM, final concentration). After incubation the samples are added 5 ml of ice-cold buffer and poured directly onto Whatman GF/C glass fibre filters under suction and immediately washed with 5 ml ice-cold buffer. The amount of radioactivity on the filters is determined by conventional liquid scintillation counting. Specific binding is total binding minus non-specific binding.

The test value is calculated as the IC<sub>50</sub> (the concentration (nM) of the test substance which inhibits the specific binding of <sup>3</sup>H-FNM by 50%).

Test results obtained by testing selected compounds of the present invention appear from the following table:

**Table**

Test compound:	IC <sub>50</sub> (nM)
5 1-(3-(1-Imidazolyl)-phenyl)-5-(3-furanyl)benzimidazole	0.4
1-(3-(2-Methyl-1-imidazolyl)-phenyl)-5-(3-furanyl)benzimidazole	0.4

10 Pharmaceutical Compositions

While it is possible that, for use in therapy, a compound of the invention may be administered as the raw chemical, then it is preferable to present the active ingredient as a pharmaceutical formulation.

15 The invention thus further provides a pharmaceutical formulation comprising a compound of the invention or a pharmaceutically acceptable salt or derivative thereof together with one or more pharmaceutically acceptable carriers therefor and, optionally, other therapeutic and/or prophylactic ingredients. The carrier(s) must be  
20 "acceptable" in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.

Pharmaceutical formulations include those suitable for oral, rectal, nasal, topical (including buccal and sub-lingual), vaginal or parenteral (including intramuscular, sub-cutaneous and intravenous) administration or in a form suitable for administration by inhalation or insufflation.

The compounds of the invention, together with a conventional adjuvant, carrier, or diluent, may thus be placed into the form of pharmaceutical compositions and unit dosages thereof, and in such form may be employed as solids, such as tablets or filled capsules, or liquids such as solutions, suspensions, emulsions, elixirs, or capsules filled with the same, all for oral use, in the form of suppositories for rectal administration; or in the form of sterile injectable solutions for parenteral (including subcutaneous) use. Such pharmaceutical compositions and unit dosage forms thereof may comprise conventional ingredients in conventional proportions, with or without

additional active compounds or principles, and such unit dosage forms may contain any suitable effective amount of the active ingredient commensurate with the intended daily dosage range to be employed. Formulations containing one (1) milligram of active ingredient or, more broadly, 0.01 to one hundred (100) milligrams, per tablet, are  
5 accordingly suitable representative unit dosage forms.

The compounds of the present invention can be administrated in a wide variety of oral and parenteral dosage forms. It will be obvious to those skilled in the art that the  
10 following dosage forms may comprise as the active component, either a compound of the invention or a pharmaceutically acceptable salt of a compound of the invention.

For preparing pharmaceutical compositions from the compounds of the present invention, pharmaceutically acceptable carriers can be either solid or liquid. Solid form preparations include powders, tablets, pills, capsules, cachets, suppositories, and  
15 dispersible granules.

A solid carrier can be one or more substances which may also act as diluents, flavouring agents, solubilizers, lubricants, suspending agents, binders, preservatives, tablet disintegrating agents, or an encapsulating material.  
20

In powders, the carrier is a finely divided solid which is in a mixture with the finely divided active component.

In tablets, the active component is mixed with the carrier having the necessary binding  
25 capacity in suitable proportions and compacted in the shape and size desired.

The powders and tablets preferably contain from one to about seventy percent of the active compound. Suitable carriers are magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, tragacanth, methylcellulose, sodium  
30 carboxymethylcellulose, a low melting wax, cocoa butter, and the like. The term "preparation" is intended to include the formulation of the active compound with encapsulating material as carrier providing a capsule in which the active component, with or without carriers, is surrounded by a carrier, which is thus in association with it. Similarly, cachets and lozenges are included. Tablets, powders, capsules, pills,  
35 cachets, and lozenges can be used as solid forms suitable for oral administration.

For preparing suppositories, a low melting vax, such as a mixture of fatty acid glycerides or cocoa butter, is first melted and the active component is dispersed homogeneously therein, as by stirring. The molten homogenous mixture is then poured 5 into convenient sized molds, allowed to cool, and thereby to solidify.

Formulations suitable for vaginal administration may be presented as pessaries, tampons, creams, gels, pastes, foams or sprays containing in addition to the active ingredient such carriers as are known in the art to be appropriate.

10

Liquid form preparations include solutions, suspensions, and emulsions, for example, water or water propylene glycol solutions. For example, parenteral injection liquid preparations can be formulated in solutions in aqueous polyethylene glycol solution.

15

The compounds according to the present invention may thus be formulated for parenteral administration (e.g. by injection, for example bolus injection or continuous infusion) and may be presented in unit dose form in ampoules, pre-filled syringes, small volume infusion or in multi-dose containers with an added preservative. The 20 compositions may take such forms as suspensions, solutions, or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilising and/or dispersing agents. Alternatively, the active ingredient may be in powder form, obtained by aseptic isolation of sterile solid or by lyophilisation from solution, for constitution with a suitable vehicle, e.g. sterile, pyrogen-free water, before use.

25

Aqueous solutions suitable for oral use can be prepared by dissolving the active component in water and adding suitable colorants, flavours, stabilizing and thickening agents, as desired.

30

Aqueous suspensions suitable for oral use can be made by dispersing the finely divided active component in water with viscous material, such as natural or synthetic gums, resins, methylcellulose, sodium carboxymethylcellulose, and other well known suspending agents.

Also included are solid form preparations which are intended to be converted, shortly before use, to liquid form preparations for oral administration. Such liquid forms include solutions, suspensions, and emulsions. These preparations may contain, in addition to the active component, colorants, flavours, stabilizers, buffers, artificial and natural

- 5 sweeteners, dispersants, thickeners, solubilizing agents, and the like.

- For topical administration to the epidermis the compounds according to the invention may be formulated as ointments, creams or lotions, or as a transdermal patch.  
Ointments and creams may, for example, be formulated with an aqueous or oily base  
10 with the addition of suitable thickening and/or gelling agents. Lotions may be formulated with an aqueous or oily base and will in general also contain one or more emulsifying agents, stabilising agents, dispersing agents, suspending agents, thickening agents, or colouring agents.

- 15 Formulations suitable for topical administration in the mouth include lozenges comprising active agent in a flavoured base, usually sucrose and acacia or tragacanth; pastilles comprising the active ingredient in an inert base such as gelatin and glycerin or sucrose and acacia; and mouthwashes comprising the active ingredient in a suitable liquid carrier.

- 20 Solutions or suspensions are applied directly to the nasal cavity by conventional means, for example with a dropper, pipette or spray. The formulations may be provided in single or multidose form. In the latter case of a dropper or pipette this may be achieved by the patient administering an appropriate, predetermined volume of the  
25 solution or suspension. In the case of a spray this may be achieved for example by means of a metering atomising spray pump.

- Administration to the respiratory tract may also be achieved by means of an aerosol formulation in which the active ingredient is provided in a pressurised pack with a  
30 suitable propellant such as a chlorofluorocarbon (CFC) for example dichlorodifluoromethane, trichlorofluoromethane, or dichlorotetrafluoroethane, carbon dioxide or other suitable gas. The aerosol may conveniently also contain a surfactant such as lecithin. The dose of drug may be controlled by provision of a metered valve.

Alternatively the active ingredients may be provided in the form of a dry powder, for example a powder mix of the compound in a suitable powder base such as lactose, starch, starch derivatives such as hydroxypropylmethyl cellulose and polyvinylpyrrolidine (PVP). Conveniently the powder carrier will form a gel in the nasal cavity. The powder composition may be presented in unit dose form for example in capsules or cartridges of e.g. gelatin or blister packs from which the powder may be administered by means of an inhaler.

In formulations intended for administration to the respiratory tract, including intranasal formulations, the compound will generally have a small particle size for example of the order of 5 microns or less. Such a particle size may be obtained by means known in the art, for example by micronization.

When desired, formulations adapted to give sustained release of the active ingredient may be employed.

The pharmaceutical preparations are preferably in unit dosage forms. In such form, the preparation is subdivided into unit doses containing appropriate quantities of the active component. The unit dosage form can be a packaged preparation, the package containing discrete quantities of preparation, such as packeted tablets, capsules, and powders in vials or ampoules. Also, the unit dosage form can be a capsule, tablet, cachet, or lozenge itself, or it can be the appropriate number of any of these in packaged form.

Tablets or capsules for oral administration and liquids for intravenous administration are preferred compositions.

#### **Method of Treating**

The compounds of this invention are extremely useful in the treatment of disorders or diseases of a living animal body due to their affinity for the benzodiazepine binding site of the GABA<sub>A</sub> receptor. These properties make the compounds of this invention extremely useful in the treatment of convulsions, anxiety, sleep disorders, memory disorders as well as other disorders sensitive to modulation of the GABA<sub>A</sub> receptor. The compounds of this invention may accordingly be administered to a subject,

including a human, in need of treatment, alleviation, or elimination of a disorder or disease associated with the GABA<sub>A</sub> receptors. This includes especially convulsions, anxiety, sleep disorders and memory disorders.

- 5   Suitable dosage range are 0.01-100 milligrams daily, 0.1-50 milligrams daily, and especially 0.1-30 milligrams daily, dependent as usual upon the exact mode of administration, form in which administered, the indication towards which the administration is directed, the subject involved and the body weight of the subject involved, and further the preference and experience of the physician or veterinarian in  
10   charge.

The following examples will illustrate the invention further; however they are not to be construed as limiting. The compounds of the invention prepared in the following examples are listed in tables 1-2 on pages 41-43.

**Example 1**

- 4-Fluoro-1-iodo-3-nitrobenzene (1c):** A suspension of 4-fluoro-3-nitroaniline (100g, 0.64mol) in conc. hydrochloric acid (500ml) is cooled to -20°C. A solution of sodium nitrite (48.6g, 0.7mol) in 100ml of water is added with stirring, keeping the temperature below -15°C. Following the addition the mixture is stirred for 45 min. at -20 - (-15)°C. To the resulting solution a solution of potassium iodide (132.8g, 0.8mol) in 260ml of water is added at such a rate that the temperature is kept below 0°C. The mixture is stirred until the evolution of nitrogen has ceased. Aqueous sodium sulfite (200ml, 1M) is added and the mixture is extracted with diethyl ether. The ethereal extract is washed twice with ice-cold 1M aqueous sodium hydroxide and twice with brine. Finally the extract is dried over magnesium sulfate, concentrated and purified by column-chromatography on silica gel using a mixture of ethyl acetate and petroleum ether (1:9) as the eluent. **1c** is isolated as an oil, which crystallizes in the refrigerator. Yield: 132.6g (78%).

**Example 2**

- 3-(5-Pyrimidyl)aniline (2b):** A suspension of 5-bromopyrimidine (15g, 94.3mmol), 3-aminophenylboronic acid hemisulfate (19.3g, 104mmol), sodium bicarbonate (39.6g, 472mmol) and tetrakis(triphenylphosphine)palladium(0) (1g) in a mixture of water (75ml) and dimethoxyethane (150ml) is heated to 80°C under a stream of nitrogen over night. After cooling the mixture is poured into ice-water. The precipitate is filtered off, washed with water and dried to yield **2b** (15g, 93%). Mp 164-165°C.
- 25 3-(2-Thiazolyl)aniline (2t)** was prepared analogously from 2-bromothiazole. The product was purified by column-chromatography using a mixture of ethyl acetate and petroleum ether (1:1) as the eluent. Yield: 25%. Mp 43-49°C.

**Example 3**

- 3-(1-Imidazolyl)aniline (2d):** A mixture of 1-iodo-3-nitrobenzene (90g, 0.36mol), imidazole (54g, 0.79mol), potassium carbonate (54g, 0.39mol) and finely divided copper powder (1g) is heated to 200°C. The melt is stirred for 2 hours under nitrogen. During the reaction water vapor is trapped by molecular sieves, placed between the

reaction vessel and the condenser. Following the reaction the mixture is cooled to 100°C and water is added. The mixture is allowed to cool to room temperature and the crude product is filtered off and dried. Recrystallization from toluene (200-250ml) affords pure *3-(1-imidazolyl)nitrobenzene* (54.2g, 79%). Mp 101-102°C.

5

To *3-(1-imidazolyl)nitrobenzene* (51.6g, 0.27mol) in acetic acid (500ml) is added palladium catalyst (5g 5% Pd on activated carbon) and the mixture is hydrogenated under pressure ( $P_{\text{start}}$ : 4bar) until the hydrogen uptake has ceased. The mixture is filtered through celite and the filtrate is evaporated to dryness to leave **2d** as a light-brown oil. Yield: 40.4g (93%).

10

*N-Acetyl 3-(1-imidazolyl)aniline (2e):* **2d** (5.88g, 37mmol) is stirred in acetic anhydride (30ml) at ambient temperature for 1 hour. The mixture is poured into ice-water and rendered alkaline by addition of aqueous sodium hydroxide (12M). The product is 15 filtered off, washed with water and dried to yield **2e** (6.34g, 85%). Mp 181-183°C.

15

#### Example 4

*3-(2-Pyridyl)aniline (2f):* To a solution of 2-(3-nitrophenyl)pyridine (prepared as 20 described in *J. Chem. Soc.* 1958 p. 1759). (12.7g, 63.5mmol) in abs. ethanol is added palladium catalyst (1.3g 5% Pd on activated carbon) and the mixture is hydrogenated at ambient pressure until the hydrogen uptake has ceased. The mixture is filtered through celite and the filtrate is concentrated under reduced pressure. The residue is purified by column-chromatography on silica gel using a mixture of ethyl acetate and 25 petroleum ether (9:1) as the eluent to afford **2f** (9.5g, 88%) as a light brown oil.

*5-(3-Furanyl)-2-(3-carboxyphenyl)aminoaniline (13r)* was prepared analogously from 12r (Example 21). Ethyl acetate was used as the eluent for the chromatographic workup. Yield: 91%. Mp 211-212°C.

30

#### Example 5

*2-(Dimethylamino)pyrimidine:* A solution of 2-chloropyrimidine (5g, 43.65mmol) in dry THF (50ml) is saturated with gaseous dimethylamine. The mixture is stirred at ambient

temperature for 1 hour followed by evaporation of solvent. The residue is partitioned between water and ethyl acetate. The aqueous phase is extracted with ethyl acetate. The combined organic phases are dried over sodium sulfate and evaporated to leave the product as a brownish oil. Yield 5.07g (94%).

5

*5-Bromo-2-(dimethylamino)pyrimidine.* The above product (5.07g, 41.22mmol) is dissolved in glacial acetic acid (25ml) and bromine (2.15ml, 41.95mmol) is added. The mixture is stirred for 30 min. at ambient temperature and then poured into ice-water. The mixture is rendered alkaline by addition of 10M sodium hydroxide. The product is 10 filtered off, washed with water and dried to yield 4.72g (57%). Mp 162-164°C.

*3-(2-(Dimethylamino)-5-pyrimidyl)aniline (2h):* A mixture of 5-bromo-2-(dimethylamino)pyrimidine (6.76g, 33.17mmol), 3-aminophenylboronic acid hemisulfat (7.4g, 39.78mmol) potassium carbonate (13.73g, 99.49mmol), 1,3-propanediol (12ml, 15 166mmol) and tetrakis(triphenylphosphine)palladium(0) (0.2g) in a mixture of water (30ml) and dimethoxyethane (60ml) is heated to 80°C under nitrogen over night. After cooling the mixture is diluted with water and ethyl acetate and is filtered through a fluted filterpaper. The layers are separated and the aqueous phase is extracted once with ethyl acetate. The combined organic phases are dried over sodium sulfate and 20 evaporated to dryness. The residue is triturated with a mixture of ethyl acetate and petroleum ether (1:1) to leave crystalline 2h (5.26g, 74%). Mp 115.5-117°C.

*N-Acetyl 3-(2-methylimidazol-1-yl)aniline (2j):* 3-(2-Methylimidazol-1-yl)aniline (11g, 63.6mmol) is added in portions to acetic anhydride (100ml) at ambient temperature. 25 After stirring for 1 hour the mixture is poured into water (300ml). The resulting solution is cooled in an ice-bath and rendered alkaline with aqueous sodium hydroxide (12M). The product is filtered off, washed thoroughly with water and dried to yield 2j (12.3g, 97%). Mp 238-240°C.

30

### Example 6

*1-(3-Nitrophenyl)pyrrol:* A mixture of 3-nitroaniline (15g, 0.11mol), 2,5-dimethoxytetrahydrofuran (42ml, 0.33mol) and a catalytic amount of pTSA in dry toluene (150ml) is heated to reflux for 2 hours. After cooling the mixture is 35 concentrated under reduced pressure and the residue is purified by column-

chromatography on silica gel using a mixture of ethyl acetate and petroleum ether (1:1) as the eluent. Yield: 16g (78%). Mp 65-70°C.

- 5      **3-(1-Pyrrolyl)aniline:** To a suspension of the above product (16g, 85.1mmol) in glacial acetic acid (100ml) is added palladium catalyst (1.5g 5% Pd on activated carbon) and the mixture is hydrogenated ( $P_{\text{start}} = 4\text{bar}$ ) until the hydrogen uptake has ceased. The mixture is filtered through celite and the solvent is removed by evaporation. The resulting crude product is used for the next step without purification.
- 10     **N-Acetyl 3-(1-pyrrolyl)aniline (2k):** To the above product is added acetic anhydride (40ml) and the mixture is stirred at ambient temperature over night. The mixture is poured into water. The crude product is filtered off, washed with water and dried. Recrystallization from a mixture of water and ethanol (3:2) affords pure **2k**. Yield: 9.93g (58%). Mp 134-136°C.

15

#### Example 7

- 20     **3-(2-Aminopyrimid-5-yl)aniline (2l):** A mixture of 2-(acetamino)-5-bromopyrimidine (5.4g, 25mmol), 3-aminophenylboronic acid hemisulfate (5.58g, 30mmol), potassium carbonate (10.4g, 75mmol), 1,3-propanediol (9ml, 0.13mmol) and tetrakis(triphenylphosphine)palladium(0) (0.5g) in a mixture of water (25ml) and dimethoxyethane (50ml) is stirred at 80°C under a stream of nitrogen over night. After cooling the mixture is poured into ice-water. The product (deacetylated during the reaction) is filtered off, washed with water and dried to yield **2l** (4.19g, 90%). Mp 171-172°C.

#### Example 8

- 30     **N-Acetyl N-(3-(1-imidazoly)phenyl)-2-nitro-4-iodoaniline (6c):** A solution of **2e** from Example 3 (30g, 0.15mol) in dry DMF (200ml) is cooled to 0°C under nitrogen. Sodium hydride (7.2g of a 60% dispersion in mineral oil) is added portionwise. When the evolution of hydrogen has ceased a solution of **1c** from Example 1 (52g, 0.19mol) in 50ml DMF is added. The mixture is stirred at 120°C for 5 hours and left at ambient temperature over night. The reaction mixture is poured into four volumes of water and

the crude product is filtered off. Purification on silica gel using a mixture of ethyl acetate and petroleum ether (3:17) as the eluent affords pure **6c** as an oil (17g, 25%).

#### Example 9

5

*N-(3-(2-Methyl-1-imidazolyl)phenyl)-2-nitro-4-iodoaniline (6j):* To a solution of **2j** from Example 5 (2g, 9.3mmol) in dry N-methyl-2-pyrrolidone (20ml) is added sodium hydride (0.37g of a 60% dispersion in mineral oil) in portions at 0°C under nitrogen. The mixture is stirred for 1 hour, the last 30 min. at room-temperature.

- 1c** from Example 1 (2.67g, 10mmol) is added and the temperature is raised to 40-50°C over night. After cooling the mixture is poured into water (100ml) and extracted with dichloromethane. The organic phase is extracted with 4M hydrochloric acid. The acidic extract is cooled in ice, rendered alkaline by addition of sodium hydroxide (12M) and extracted with dichloromethane. The organic phase is dried over magnesium sulfate and evaporated to dryness. The residue is extracted with a mixture of dichloromethane and diethyl ether (1:1). This extract is concentrated under reduced pressure and the residue is dissolved in dimethoxyethane (60ml). Aqueous sodium hydroxide (28ml, 1M) is added and the mixture is stirred at ambient temperature over night. The mixture is poured into water (200ml) and a small volume of ethanol is added with stirring. The product is filtered off, washed with water and dried to leave **6j** (2g, 51%). Mp 135-136°C.

*N-(3-(1-Pyrrolyl)phenyl)-2-nitro-4-nitroaniline (6k)* was prepared analogously from **1c** (Example 1) and **2k** (Example 6). Yield: 30%. Mp 116-118°C.

25

#### Example 10

*N-(3-(2-(Dimethylamino)pyrimid-5-yl)phenyl)-2-nitro-4-iodoaniline hydrofluoride (6h):* A mixture of **1c** from Example 1 (3g, 11.2mmol) and **2h** from Example 5 (2.4g,

- 30** 11.2mmol) in dry N-methyl-2-pyrrolidone (10ml) is stirred under nitrogen at 120-135°C for 6 hours. The mixture is allowed to cool to room temperature and stirring is continued over night. To the resulting suspension is added water. The product is filtered off, dried and washed with ethyl acetate to afford **6h** (3.46g, 64%). Mp 202-203°C.

*N-(3-(2-aminopyrimid-5-yl)phenyl)-2-nitro-4-iodoaniline hydrofluoride (6l)* was prepared analogously from **1c** (Example 1) and **2l** (Example 7). Yield: 79%. Mp 236-238°C.

- 5   *N-(3-(1-Pyrazolyl)phenyl)-4-iodo-2-nitroaniline (6m)* was prepared analogously from **1c** (Example 1) and **2m** (Example 16). The base was liberated by treatment with aqueous sodium carbonate. Yield: 23%. Mp 165-166°C.

- 10   *N-(3-(2-Methylthiazol-4-yl)phenyl)-4-iodo-2-nitroaniline (6n)* was prepared analogously from **1c** (Example 1) and **2n** (Example 17). Yield: 32%. Mp 137-138°C.

*N-(3-(5-Pyrimidyl)phenyl)-4-iodo-2-nitroaniline (6b)* was prepared analogously from **1c** (Example 1) and **2b** (Example 2). Yield 79%. Mp 214-217°C.

- 15   *N-(3-(2-Pyridyl)phenyl)-4-iodo-2-nitroaniline (6f)* was prepared analogously from **1c** (Example 1) and **2f** (Example 4). Yield: 40%. Mp 195-196°C.

### Example 11

- 20   *N-(3-(1-Imidazolyl)phenyl)-4-(3-furanyl)-2-nitroaniline (7c)*: A mixture of **6c** from Example 8 (17g, 38mmol), 3-furanylboronic acid (5.6g, 50mmol), 1,3-propanediol (14ml, 0.17mol), potassium carbonate (15.7g, 0.11mol) and tetrakis(triphenylphosphine)palladium(0) (0.5g) in a mixture of water (60ml) and dimethoxyethane (120ml) is refluxed under nitrogen for 4 hours. After cooling the mixture is poured into water (800ml) and is stirred at 0°C until the precipitation of oily crystals is complete. This crude product (a mixture of acetylated and deacetylated product) is filtered off and dissolved in dimethoxyethane (200ml). Aqueous sodium hydroxide (114ml, 1M) is added and the mixture is stirred at ambient temperature over night. The mixture is poured into water (500ml) and the product is filtered off, washed with water and dried. Yield: 13.1g (100%). Mp 129-131°C.

*N-(3-(1-Imidazolyl)phenyl)-4-(2-furanyl)-2-nitroaniline (7o)* was prepared analogously from **6c** (Example 8) and 2-furanylboronic acid. Yield: 77%. Mp 147-149°C.

**Example 12**

*N-(3-(2-Methylimidazol-1-yl)phenyl)-4-(3-furanyl)-2-nitroaniline (7j)*: A mixture of **6j** from Example 9 (1g, 2.38mmol), 3-furanylboronic acid (0.4g, 3.57mmol), potassium carbonate (1g, 7.25mmol), 1,3-propanediol (0.9ml, 11.2mmol) and tetrakis(triphenylphosphine)palladium(0) (50mg) in a mixture of dimethoxyethane (7ml) and water (3.5ml) is heated to reflux under nitrogen for 4 hours. After cooling the mixture is poured into water (30ml) and extracted with ethyl acetate. The organic phase is dried over magnesium sulfate and concentrated under reduced pressure. The residue is purified by column-chromatography on silica gel using a mixture of ethanol and ethyl acetate (1:4) as the eluent. Yield: 0.8g (93%). The product was isolated as an oil.

*N-(3-(2-(Dimethylamino)pyrimid-5-yl)phenyl)-4-(3-furanyl)-2-nitroaniline (7h)* was prepared analogously from **6h** (Example 10) in 87% yield. Mp 181-182°C.

*N-(3-(2-(Dimethylamino)pyrimid-5-yl)phenyl)-4-(2-furanyl)-2-nitroaniline (7m)* was prepared analogously from **6h** (Example 10) and 2-furanylboronic acid in 89% yield. Mp 160-161°C.

*N-(3-(1-Pyrrolyl)phenyl)-4-(3-furanyl)-2-nitroaniline (7k)* was prepared analogously from **6k** (Example 9) and 3-furanylboronic acid. Yield: 86%. Mp 129-131°C.

*N-(3-(1-Pyrrolyl)phenyl)-4-(2-furanyl)-2-nitroaniline (7n)* was prepared analogously from **6k** (Example 9) and 2-furanylboronic acid. Yield: 83%. Isolated as a brownish-red oil.

*N-(3-(2-Aminopyrimid-5-yl)phenyl)-4-(3-furanyl)-2-nitroaniline (7l)* was prepared analogously from **6l** (Example 10) and 3-furanylboronic acid in quantitative yield. Mp 185-186°C.

*N-(3-(2-Aminopyrimid-5-yl)phenyl)-4-(2-furanyl)-2-nitroaniline (7p)* was prepared analogously from **6l** (Example 10) and 2-furanylboronic acid in quantitative yield. Mp 178-180°C.

*1-(3-(5-Pyrimidyl)phenyl)-5-(3-furanyl)benzimidazole (9b)* was prepared analogously from **11b** (Example 15) and 3-furanylboronic acid. A mixture of dichloromethane and methanol (19:1) was used as eluent for the chromatographic purification. Yield: 48%.

5 Mp 216-218°C.

*1-(3-(2-Methylthiazol-4-yl)-5-(3-furanyl)benzimidazole (9N)* was prepared analogously from **11n** (Example 15) and 3-furanylboronic acid. A mixture of ethyl acetate and petroleum ether (1:1) was used as eluent for the chromatographic purification. Yield:

10 73%. Mp 136-138°C.

*1-(3-(1-Pyrazolyl)phenyl)-5-(3-furanyl)benzimidazole (9M)* was prepared analogously from **11m** (Example 15) and 3-furanylboronic acid. Yield: 64%. Mp 170-173°C.

15 *1-(3-(2-Pyridyl)phenyl)-5-(2-furanyl)benzimidazole (9f)* was prepared analogously from **11f** (Example 15) and 2-furanylboronic acid. The crude product was purified by treatment of an ethanolic solution with activated carbon. Yield: 42%. Mp 135-136°C.

20 *1-(3-(3-Furanyl)phenyl)-5-(3-furanyl)benzimidazole (9q)* was prepared analogously from **14q** (Example 15). Yield: ~15%. Mp 149-150°C.

*N-(2-(1-Imidazolyl)pyridin-6-yl)-4-(3-furanyl)-2-nitroaniline (16c)* was prepared analogously from **16a** (Example 25). Chromatographic workup was omitted. The product crystallizes quantitatively upon addition of water. Mp 173-174°C.

25

### Example 13

*N-(3-(1-Imidazolyl)phenyl)-2-amino-4-(3-furanyl)aniline (8c):* To a solution of **7c** from Example 11 (13 g, 37.6 mmol) in ethanol (25 ml) is added ammonium chloride (6.03 g, 113 mmol) and sodium sulfide nonahydrate (27.05 g, 113 mmol). The mixture is heated to reflux for 1 hour. After cooling the mixture is poured into 700 ml of water. The product is filtered off, washed with water and air-dried to yield **8c** ( 8.7 g, 73%). Mp 188-189°C.

*N-(3-(2-Methylimidazol-1-yl)phenyl)-2-amino-4-(3-furanyl)aniline (8j)* was prepared analogously from **7j** (Example 12) in quantitative yield. Mp 98-99°C.

*N-(3-(1-Pyrrolyl)phenyl)-2-amino-4-(3-furanyl)aniline (8k)* was prepared analogously  
5 from **7k** (Example 12). Yield: 80%. Mp 194-195°C.

*N-(3-(1-Imidazolyl)phenyl)-2-amino-4-(2-furanyl)aniline (8o)* was prepared analogously from **7o** (Example 11). Yield: 94%. Mp 191-194°C.

10 *N-(3-(1-Pyrrolyl)phenyl)-2-amino-4-(2-furanyl)aniline (8n)* was prepared analogously from **7n** (Example 12). Yield: 77%. Mp 163-164°C.

*N-(3-(2-(Dimethylamino)pyrimid-5-yl)phenyl)-2-amino-4-(3-furanyl)aniline (8h)* was prepared analogously from **7h** (Example 12). Isolated as an oil.

15 *N-(3-(2-(Dimethylamino)pyrimid-5-yl)phenyl)-2-amino-4-(2-furanyl)aniline (8m)* was prepared analogously from **7m** (Example 12). Isolated as an oil.

20 *N-(3-(1-Pyrazolyl)phenyl)-2-amino-4-iodoaniline (10m)* was prepared analogously from **6m** (Example 10). Yield: 75%. Mp 134-135°C.

*N-(3-(5-Pyrimidyl)phenyl)-2-amino-4-iodoaniline (10b)* was prepared analogously from **6b** (Example 10). Yield 82%. Mp 166-169°C.

25 *N-(3-(2-Pyridyl)phenyl)-2-amino-4-iodoaniline (10f)* was prepared analogously from **6f** (Example 10). The product was used directly for the next step. See Example 15.

*N-(3-(2-Methylthiazol-4-yl)phenyl)-2-amino-4-iodoaniline (10n)* was prepared analogously from **6n** (Example 10). Yield: 73%. Mp 151-152°C.

30 *N-(3-Bromophenyl)-2-amino-4-(3-furanyl)aniline* in mixture with *N-(3-iodophenyl)-2-amino-4-(3-furanyl)aniline (13q)* was prepared analogously from **12q** (Example 20). The product mixture was isolated as an oil. Yield: ~76%.

*N-(3-(2-Thiazolyl)phenyl)-2-amino-4-nitroaniline (20t)* was prepared analogously from **19t** (Example 27). Yield: 96%. Mp 146-159°C.

#### Example 14

5

*N-(3-(2-Aminopyrimid-5-yl)phenyl)-2-amino-4-(2-furanyl)aniline (8l)*

- To a suspension of **7p** from Example 12 (0.87 g, 2.33 mmol) in ethanol (10 ml) is added 0.1 g palladium catalyst (5% Pd on activated carbon) and the mixture is hydrogenated at ambient pressure until the hydrogen uptake has ceased. The mixture 10 is filtered through celite, which is washed with ethanol and DMF successively. The filtrate is evaporated under reduced pressure, and the residue is triturated with water. The product is filtered off, washed with water and air-dried to yield **8l** (0.5 g, 63%). Mp 211-212°C.
- 15 *N-(3-(2-Aminopyrimid-5-yl)phenyl)-2-amino-4-(3-furanyl)aniline (8p): 7l* (Example 12) is hydrogenated as described above to yield **8p** (43%). Mp 208-209°C.

#### Example 15

- 20 *1-(3-(1-Imidazolyl)phenyl)-5-(3-furanyl)benzimidazole (9c):* A solution of **8c** from Example 13 (8.7 g, 27.5 mmol) in formic acid (100 ml) is heated to reflux for 30 min. After cooling the mixture is poured into water (500 ml) and rendered alkaline by addition of aqueous sodium hydroxide (12M). The crude product is filtered off, washed with water and air-dried. A solution of this crude product in a mixture of ethanol (200 ml) and dichloromethane (400 ml) is treated with activated carbon at reflux for 15 min. The mixture is filtered through celite and the filtrate is concentrated under reduced pressure until onset of precipitation. Precipitation is completed by cooling in an ice-bath. The product is filtered off and dried. Yield: 7.5 g (84%) Mp. 203-204 °C.
- 25 *1-(3-(2-(Dimethylamino)pyrimid-5-yl)phenyl)-5-(3-furanyl)benzimidazole (9h)* was prepared analogously from **8h** (Example 13). Purification was achieved by column-chromatography on silica gel using a mixture of dichloromethane and acetone (9:1) as the eluent. Yield: 32% (from **7h**). Mp 183-184°C.

1-(3-(2-Methylimidazol-1-yl)phenyl)-5-(3-furanyl)benzimidazole (**9j**) was prepared analogously from **8j** (Example 13). Purification was achieved by column-chromatography on silica gel using a mixture of ethyl acetate and methanol (9:1) as the eluent. Yield: 71%. Mp 105-107°C.

5

1-(3-(1-Pyrrolyl)phenyl)-5-(3-furanyl)benzimidazole (**9k**) was prepared analogously from **8k** (Example 13). Purification was achieved by column-chromatography on silica gel using a mixture of ethyl acetate and petroleum ether (1:1) as the eluent. Yield: 42%. Mp 144-145°C.

10

1-(3-(2-Aminopyrimid-5-yl)phenyl)-5-(2-furanyl)benzimidazole (**9l**) was prepared analogously from **8l** (Example 14). Purification was achieved by column-chromatography on silica gel using a mixture of ethyl acetate and methanol (9:1) as the eluent. Yield: 11%. Mp 220-222°C.

15

1-(3-(2-(Dimethylamino)pyrimid-5-yl)phenyl)-5-(2-furanyl)benzimidazole (**9m**) was prepared analogously from **8m** (Example 13). Purification was achieved by column-chromatography on silica gel using a mixture of ethyl acetate and petroleum ether (1:1) as the eluent. Yield: 42% (from **7m**). Mp 170-172°C.

20

1-(3-(1-Pyrrolyl)phenyl)-5-(2-furanyl)benzimidazole (**9n**) was prepared analogously from **8n** (Example 13) and purified as described for **9m**. Yield: 53%. Mp 137-139°C.

25

1-(3-(1-Imidazolyl)phenyl)-5-(2-furanyl)benzimidazole (**9o**) was prepared analogously from **8o** (Example 13) and purified as described for **9c**. Yield: 46%. Mp 175-177°C.

1-(3-(2-Aminopyrimid-5-yl)phenyl)-5-(3-furanyl)benzimidazole (**9p**) was prepared analogously from **8p** (Example 14) and purified as described for **9l**. Yield: 5%. Mp 222-223°C.

30

1-(3-(5-Pyrimidyl)phenyl)-5-iodobenzimidazole (**11b**) was prepared analogously from **10b** (Example 13). The crude product was used without further purification. Yield: 91%. Mp 197-199°C.

1-(3-(2-Methylthiazol-4-yl)phenyl)-5-iodobenzimidazole (**11n**) was prepared analogously from **10n** (Example 13). Yield: 98%. Mp 163-164°C.

1-(3-(1-Pyrazolyl)phenyl)-5-iodobenzimidazole (**11m**) was prepared analogously from 5 **10m** (Example 13). Yield: 86%. Mp 209-211°C.

1-(3-(2-Pyridyl)phenyl)-5-iodobenzimidazole (**11f**) was prepared analogously from **10f** (Example 13). Yield: 53% (from **6f**). Mp 157-158°C.

10 1-(3-Bromophenyl)-5-(3-furanyl)benzimidazole in mixture with 1-(3-iodophenyl)-5-(3-furanyl)benzimidazole (**14q**) was prepared analogously from **13q** (Example 13). The crude product was used without purification (Example 12). Yield: 47%.

15 1-(4-(1-Imidazolyl)pyrimid-6-yl)-5-(3-furanyl)benzimidazole (**18b**) was prepared analogously from **17b** (Example 26). Yield: 27% (from **16b**). Mp 294-296°C.

1-(2-(1-Imidazolyl)pyridin-6-yl)-5-(3-furanyl)benzimidazole (**18c**) was prepared analogously from **17c** (Example 26). The product was isolated by extraction and crystallization from ethyl acetate. Yield: 29%. Mp 170-173°C.

20 1-(3-(2-Thiazolyl)phenyl)-5-nitrobenzimidazole (**21t**) was prepared analogously from **20t** (Example 13) in quantitative yield. Mp 251-260°C.

### Example 16

25 1-(3-Nitrophenyl)pyrazol. A mixture of 1-iodo-3-nitrobenzene (18.7 g, 75 mmol), pyrazol (7.66 g, 113 mmol), potassium carbonate (11.2 g, 81 mmol) and catalytic amounts of cuprous iodide and copper-bronze in dry N-methyl-2-pyrrolidone (50 ml) is heated to 180 °C for 4.5 hours. After cooling the mixture is filtered through celite. The 30 filtrate is poured into ice water (700 ml) and the product is filtered off, washed with water and dried to yield 13.57 g. Yield: 96%. Mp 85-87°C.

3-(1-Pyrazolyl)aniline (**2m**): A suspension of 3-(1-pyrazolyl)-1-nitrobenzene (5.5g, 34.6mmol) in conc. hydrochloric acid (50ml) is heated to reflux. Stannous chloride

dihydrat (24.2g, 0.11mol) is added portionwise and reflux is continued for half an hour. After cooling the precipitate is filtered off and dissolved in 200ml water. The resulting solution is cooled in an ice-bath, rendered alkaline by addition of 12M aqueous sodium hydroxide and extracted with ethyl acetate. The extract is washed with brine, dried over 5 sodium sulfate and evaporated to leave the product as a brownish oil. Yield: 3.9g (71%).

10 *1-(3-(2-Thiazoly)phenyl-5-aminobenzimidazole (22t)* was prepared analogously from **21t** (Example 15). Isolated as an oil. Yield: 65%.

#### Example 17

15 *3-(2-Methylthiazol-4-yl)aniline (2n)*: A mixture of 2-bromo-3'-nitroacetophenone (5g, 20.5mmol) and thioacetamide (1.4g, 18.6mmol) in glacial acetic acid (50ml) is heated to reflux over night. After cooling the precipitate is filtered off, washed with water and dried to yield *2-methyl-4-(3-nitrophenyl)thiazole* (3.47g, 85%). Mp 87-88°C. This product is hydrogenated as described in Example 4 to yield **2n** quantitatively. Mp 80-81°C.

#### Example 18

20 *N-Acetyl 4-bromo-2-nitroaniline (1d)*: A solution of 4-bromoacetanilide (20g, 93.4mmol) in methanesulfonic acid is cooled to 10°C. Conc. nitric acid (12.6ml) is added and the mixture is stirred at 40°C for 2 hours. The mixture is poured into ice-water. The product is filtered off, washed with water and dried. Yield: 23.59g (97%). Mp 99-100°C.

25 *4-Bromo-2-nitroaniline (1f)*: A mixture of **1d** (3.5g, 13.5mmol), dimethoxyethane (100ml) and aqueous sodium hydroxide (50ml, 1M) is heated to 80°C for 1 hour. After cooling the mixture is poured into ice-water. The product is filtered off, washed with water and dried. Yield 2.77g (94%). Mp 109-110°C.

30 *Example 19*

*N-Acetyl 4-(3-furanyl)-2-nitroaniline (1e)*: A mixture of **1d** from Example 18 (8.5g, 32.8mmol), 3-furanylboronic acid (3.67g, 32.8mmol), sodium bicarbonate (13.8g,

0.16mol) and tetrakis(triphenylphosphine)palladium(0) (0.5g) in a mixture of water (40ml) and dimethoxyethane (80ml) is heated to 80°C under a stream of nitrogen over night. After cooling the mixture is poured into water and extracted with ethyl acetate. The organic phase is washed with brine, dried over sodium sulfate and concentrated 5 under reduced pressure. (\*) The residue is dissolved in 40ml dimethoxyethane. Aqueous sodium hydroxide (78ml, 1M) is added and the mixture is stirred at ambient temperature over night. The mixture is poured into water and rendered acidic with diluted hydrochloric acid. The precipitate is filtered off, washed with water and dried to yield **1e** (5.09g, 76%). Mp 152-154°C.

10

**1-(3-(2-Thiazolyl)phenyl)-5-(3-furanyl)benzimidazole (9t)** was prepared analogously from 23t (Example 28) until (\*). The residue was eluted through silica gel with a mixture of ethyl acetate and petroleum ether (1:1). Yield: 9%. Mp 102-105°C.

15

#### Example 20

**N-(3-Bromophenyl)-4-(3-furanyl)-2-nitroaniline** in mixture with **N-(3-iodophenyl)-4-(3-furanyl)-2-nitroaniline (12q)**: A mixture of 1-bromo-3-iodobenzene (2.65ml, 20.8mmol), **1e** from Example 19 (4g, 19.6mmol), potassium carbonate (2.93g, 21.2mmol) and a 20 catalytic amount of copper-bronze in dry N-methyl-2-pyrrolidone is heated to 180°C over night. After cooling the mixture is poured into water. Ethyl acetate is added and the mixture is filtered through celite. The phases are separated and the aqueous phase is extracted twice with ethyl acetate. The combined organic extracts are dried over sodium sulfate and the solvent is removed under reduced pressure. The residue 25 is purified by column-chromatography on silica gel using a mixture of ethyl acetate and petroleum ether (1:9) as the eluent. The product-mixture (**12q**) is isolated as a red oil (1.44g) which is used directly in the next step (see Example 13).

#### Example 21

30

**N-(3-Carboxyphenyl)-4-(3-furanyl)-2-nitroaniline (12r)**: A mixture of **1e** from Example 19 (5g, 24.5mmol), 3-iodobenzoic acid (6.69g, 27mmol), potassium carbonate (3.79g, 27.5mmol) and a catalytic amount of copper-bronze in 30ml dry N-methyl-2-pyrrolidone is heated to 180°C overnight. After cooling water is added and the mixture is washed

twice with ethyl acetate. The aqueous phase is rendered acidic with diluted hydrochloric acid and the oily precipitate is filtered off. This precipitate is extracted with ethyl acetate, and the extract is purified by column-chromatography on silica gel using a mixture of ethyl acetate and petroleum ether (1:1) as the eluent. Yield: 2.56g (32%).

5 Mp 203-205°C.

### Example 22

1-(3-Carboxyphenyl)-5-(3-furanyl)benzimidazole (14r): To 13r from Example 4 (2.4g, 10 8.16mmol) is added formic acid (25ml) and the mixture is stirred at 80°C for 1.5 hours. After cooling the mixture is poured into ice-water. The precipitate is filtered off, washed with methanol and dried to yield 14r (0.89g, 40%). Mp 272-274°C.

1-(3-(3-(2-Pyridyl)oxadiazol-5-yl)phenyl)-5-(3-furanyl)benzimidazole (9r): A solution of 15 14r (0.43g, 1.41mmol) in dry THF (10ml) is heated to reflux under nitrogen. Carbonyldiimidazole (0.4g, 2.48mmol) is added and reflux is continued for 3 hours. 2-(Oximimido)pyridine (0.48 g, 3.54 mmol) is added and the resulting mixture is refluxed over night. After cooling the solvent is removed by evaporation and the residue is partitioned between water and ethyl acetate. The organic phase is dried over 20 sodium sulfate and evaporated to dryness. The residue is dissolved in toluene (15ml), a catalytic amount of pTSA is added and the mixture is refluxed over night. The solvent is evaporated under reduced pressure and the residue is purified by column-chromatography on silica gel using a mixture of ethyl acetate and petroleum ether (1:1) as the eluent. Yield of 9r: 0.16g (28%). Mp 183-186°C.

25

1-(3-(3-Cyclopropyloxadiazol-5-yl)phenyl)-5-(3-furanyl)benzimidazole (9s) was prepared analogously from 14r and cyclopropyloximimide. Yield: 19%. Mp 144-146°C.

### Example 23

30

2-Chloro-6-(1-imidazolyl)pyridine (15a): A mixture of 2,6-dichloropyridine (5g, 33.78mmol), imidazole (2.3g, 33.78mmol) and potassium carbonate (4.66g, 33.78mmol) in DMF (50ml) is heated to 85°C over night. The cooled mixture is poured into ice-water and unreacted starting material is filtered off. The filtrate is acidified with

diluted hydrochloric acid and is extracted once with ethyl acetate. The aqueous phase is rendered alkaline by addition of aqueous sodium hydroxide (10M) and extracted with ethyl acetate. The organic extract is dried over sodium sulfate, concentrated under reduced pressure and eluted through silica gel with a mixture of ethyl acetate and methanol (9:1). Evaporation of solvent leaves 15a. Yield: 2.37g (39%). Mp 71-73°C.

#### Example 24

**4-Chloro-6-(1-imidazolyl)pyrimidine (15b):** A mixture of 4,6-dichloropyrimidine (5g, 10 33.56mmol), imidazole (2.28g, 33.56mmol) and potassium carbonate (4.63g, 33.56mmol) in DMF (50ml) is stirred at room temperature over night. The mixture is diluted with four volumes of water and extracted with dichloromethane. The organic extract is concentrated under reduced pressure and eluted through silica gel with a mixture of ethyl acetate and methanol (9:1). Evaporation of solvent and trituration of 15 the residue with a mixture of diethyl ether and petroleum ether (1:1) leaves 15b (4.07g, 67%). Mp 198-200°C.

#### Example 25

**N-(2-(1-Imidazolyl)pyridin-6-yl)-4-bromo-2-nitroaniline (16a):** To a solution of 1f from Example 18 (2.7g, 12.5mmol) in dry DMF (25ml) is added sodium hydride (0.5g of a 60% dispersion in mineral oil) and the mixture is stirred for 30 min. 15a (Example 23) (2.25g, 12.5mmol) is added and the mixture is heated to 100°C over night. After cooling the mixture is poured into ice-water. The precipitate is filtered off, dried and 25 redissolved in ethyl acetate. The filtrate is extracted with ethyl acetate. The combined product solutions are concentrated and purified by column-chromatography on silica gel using a mixture of ethyl acetate and methanol (9:1) as the eluent. Evaporation of solvent and trituration of the residue with a mixture of petroleum ether and diethyl ether (1:1) affords 16a (0.93g, 21%). Mp 194-195°C.

30 **N-(4-(1-Imidazolyl)pyrimid-6-yl)-4-(3-furanyl)2-nitroaniline (16b)** was prepared analogously from 15b (Example 24) and 1e (Example 19). Ethyl acetate was used as the eluent for the chromatographic workup. Yield: 23%. Mp 198-200°C.

**Example 26*****N-(4-(1-Imidazolyl)pyrimid-6-yl)-2-amino-4-(3-furanyl)aniline (17b)***

- 5 A suspension of **16b** (Example 25) ( 0.38 g, 1.1 mmol) in a mixture of ethanol and dichloromethane is hydrogenated at ambient temperature using Raney Nickel (50% slurry in water) as the catalyst. When the hydrogen uptake has ceased the mixture is filtered through celite and the filtrate is evaporated to leave **17b** as an oil which is used without purification.

10

***N-(2-(1-Imidazolyl)pyrid-6-yl)-2-amino-4-(3-furanyl)aniline (17c)***

- A suspension of **16c** from Example 12 ( 0.9 g, 2.6 mmol) in 50 ml a mixture of ethanol and dichloromethane (4:1) is added Pd catalyst (0.15 g, 5% on activated carbon) and hydrogenated at ambient temperature until the hydrogen uptake has ceased. The 15 mixture is filtered through celite and the filtrate is evaporated to leave **17c** as an oil which is used without purification.

**Example 27**

- 20 ***N-(3-(2-Thiazolyl)phenyl)-2,4-dinitroaniline (19t)***: A mixture of 2,4-dinitrofluorobenzene (1.14ml, 9.1mmol), **2t** from Example 2 (1.6g, 9.1mmol) and potassium carbonate (1.51g, 10.9mmol) in dry N-methyl-2-pyrrolidone (10ml) is heated to 80°C for 2 hours. The cooled mixture is poured into ice-water. The precipitate is filtered off, washed with water and dried to yield: 3.05g (98%). Mp 197-203°C.

25

**Example 28**

- 30 ***1-(3-(2-Thiazolyl)phenyl)-5-iodobenzimidazole (23t)***: A suspension of **22t** from Example 16 (0.85g, 2.91mmol) in hydrochloric acid is cooled to -5°C. A solution of sodium nitrite (0.22g, 3.2mmol) in 3ml water is added dropwise keeping the temperature below 0°C. Following the addition the mixture is stirred at (-5)-0°C for 20 min. A solution of potassium iodide (0.6g, 3.64mmol) in 3ml water is added and the mixture is stirred at ambient temperature over night. To the reaction mixture is added aqueous sodium sulfite until the iodine color has disappeared. The resulting mixture is

extracted with ethyl acetate. The organic phase is washed with aqueous sodium carbonate, dried over sodium sulfate and filtered through silica gel. The filtrate is evaporated to dryness to yield 23t. Yield: 23%. Melts with decomposition from 175°C.

5

**Eksempel 29**

*N-(3-iodophenyl)-4-cyano-2-nitroaniline (29):* To a solution of 4-chloro-3-nitrobenzonitril (1.82 g, 10 mmol) in dry DMF (25 ml) is added triethylamine (1.54 ml, 11 mmol) and 3-idoaniline (1.2 ml, 10 mmol) and the mixture is heated to 80-100°C over night. After cooling the mixture is poured into four volumes of ice-water. The precipitate is filtered off, washed with water and dried. This crude product is washed with hot ethanol to yield 2.1 g (58%) of the title compound. Mp. 211-212°C.

**Example 30**

15

*2-amino-(N-(3-iodophenyl))-4-cyanoaniline (30):* To a suspension of (29) : (2.1 g, 5.75 mmol) in methanol (50 ml) is added ammonium chloride (0.92 g, 17.25 mmol) and sodium sulfide nonahydrate (4.14 g, 17.25 mmol) and the mixture is heated to reflux for 1.5 hours. After cooling the mixture is poured into ice-water (200 ml) and the product is filtered off, washed with water and dried to leave 1.8 g (93%) of the title compound. Mp. 170-172 °C.

**Example 31**

25

*5-cyano-1-(3-iodophenyl)benzimidazole (31):* A suspension of (30) (1.8 g, 5.36 mmol) in formic acid (20 ml) is heated to 80-100 °C for 1.5 hours. The hot reaction mixture is filtered through a cotton pad into ice-water (100 ml). The precipitate is filtered off, washed with water and dried. This crude product is dissolved in dichloromethane and is brought to precipitation by addition of petroleum ether. The product is filtered off and dried. Yield: 1.38 g (75%) of the title compound. Mp. 177-179 °C.

**Example 32**

5-cyano-1-(3-(3-pyridyl)phenyl)benzimidazol (**32a**): A mixture of (**31**) (4 g, 11.6 mmol), diethyl 3-pyridylborane (2.04 g, 13.9 mmol), potassium carbonate (4.8 g, 34.8 mmol) 5 and tetrakis(triphenylphosphine)palladium(0) (0.2 g) in a mixture of water (20 ml) and dimethoxyethane is stirred at 80 °C in a nitrogen atmosphere overnight. After cooling the resulting suspension is poured into water and the crude product is filtered off, washed with water and dried. Purification is achieved by column-chromatography on silica gel using a mixture of ethyl acetate and methanol (9:1) as the eluent. Yield 2.46 g 10 (72%) of the title compound. Mp.191-193°C.

5-cyano-1-(3-(1-imidazolyl)phenyl)benzimidazol (**32b**) was prepared analogously.

**Example 33**

15

2-Tributylstannyli(thiazole) (**33**): To a solution of thiazol (0.71 ml, 10 mmol) in dry THF (20 ml) was added dropwise 1.6 M-BuLi in hexane (6.9 ml, 11 mmol) under argon at -78°C. The reaction mixture was stirred at -78°C for 0.5 hr and Bu<sub>3</sub>SnCl (3.1 ml, 11 mmol) was added dropwise. After stirring for 1 hr at -78°C and for 1 hr at room 20 temperature, the mixture was concentrated, triturated with water (50 ml) and extracted with diethylether (100 ml x 3). The extract was washed with brine, dried and concentrated under reduced pressure to give (**33**) as colorless oil.(3.7g, quant.).

**Example 34**

25

5-Acetyl-1-(3-(2-thiazolyl)phenyl)benzimidazole (**34**): To a solution of (**33**) (3.6 g, 9.7 mmol) in dry THF (20 ml) was added 5-acetyl-1-(3-bromophenyl)benzimidazole (1.5 g, 4.8 mmol) and (PPh<sub>3</sub>)<sub>2</sub>PdCl<sub>2</sub> (340 mg, 0.48 mmol) under argon. The reaction mixture was stirred at 80°C for 24 hr in a 50 ml sealed tube. After cooling 30 the mixture was concentrated, triturated with water (100 ml) and extracted with CH<sub>2</sub>Cl<sub>2</sub> (200 ml x 3). The extract was washed with brine, dried and concentrated under reduced pressure. The residue was washed with ether to afford crystalline (**34**) (1.5 g, 89%).

*5-Acetyl-1-(3-bromophenyl)benzimidazole* was prepared as follows:

- 4-Acetyl-2-nitroaniline: N-(4-acetyl-2-nitrophenyl)acetamide (26.5 g, 11.94 mmol)  
5 was added to a mixture of water and concentrated sulfuric acid, 150 ml (1:2). After  
15 minutes the mixture was poured into water. The product was filtered off,  
washed with water and dried.

- N-(3-bromophenyl)-4-acetyl-2-nitroaniline: A mixture of 4-acetyl-2-nitroaniline (3.41  
10 g, 18.94 mmol), 1,3-dibromobenzene (4.6 ml, 38.06 mmol), potassium carbonate  
(2.62 g, 19 mmol) and a catalytic amount of copper bronze is heated with stirring to  
180 °C under a stream of nitrogen for 2 days. After cooling the solid reaction cake  
is extracted with a mixture of dichloromethane and methanol (9:1). The extract is  
concentrated under reduced pressure. The residue is extracted with ethyl acetate.  
15 This extract is concentrated under reduced pressure and the residue is eluted  
through silica gel with a mixture of petroleum ether and ethyl acetate (4:1) to afford  
the pure product. Yield 0.67 g (10.6 %). M.p. 142-144°C.

- 5-Acetyl-1-(3-bromophenyl)benzimidazole: N-(3-bromophenyl)-4-acetyl-2-nitro-  
20 aniline (9.0 g, 26.63 mmol) was suspended in 99% ethanol (100 ml). Raney nickel  
was added and the mixture was hydrogenated at ambient pressure for 20 hours.  
Chloroform was added. The mixture was filtered through celite and evaporated in  
vacuo to afford 8.03 g oil. To this oil 80 ml formic acid was added and the mixture  
was heated to 80 °C for 1.5 hours. Excess formic acid was removed in vacuo. The  
25 residue was stirred in water and rendered alkaline with aqueous sodium  
hydroxide. The product was filtered off washed with water and dried.

#### Example 35

- 30 5-Cyano-1-(3-(2-thiazolyl)phenyl)benzimidazole (35): 5-cyano-1-(3-(2-  
thiazolyl)phenyl)benzimidazole was synthesized as described in Example 34 by  
using (31) (2.0 g, 5.9 mmol) instead of 5-acetyl-1-(3-bromophenyl)benzimidazole,

( $\text{PPh}_3)_2\text{PdCl}_2$  (100 mg, 0.14 mmol) and 2-(tributylstannylyl)thiazole (3.6 g, 9.7 mmol). The reaction gave 5-cyano-1-(3-(2-thiazolyl)phenyl)benzimidazole (1.5 g, 86%).

#### Example 36

5

- 4-(3-Nitrophenyl)pyrimidine (36):** A mixture of 4-phenylpyrimidine (10 g, 64 mmol) and conc.  $\text{H}_2\text{SO}_4$  (33 ml) was added to a mixture of conc.  $\text{H}_2\text{SO}_4$  (22 ml) and conc.  $\text{HNO}_3$  (16 ml) at 0°C. The resulting mixture was stirred at 0°C for 2 hr, poured onto crushed ice, and extracted with  $\text{CH}_2\text{Cl}_2$ . The extract was washed with a 5% aqueous  $\text{NaHCO}_3$  solution, dried over  $\text{MgSO}_4$  and concentrated under reduced pressure. The residue was triturated with isopropanol and the precipitate was filtered off and dried under reduced pressure to give (36) (6.4 g, 50%).

#### Example 37

15

- 4-(3-Aminophenyl)pyrimidine (37):** To a suspension of (36) (6.3 g, 31 mmol) in a mixture of MeOH (60 ml) and THF (30 ml) was added 5% palladium on activated carbon (300 mg) and the mixture was hydrogenated at ambient pressure for 1 hr. The mixture was filtered and concentrated under reduced pressure. The residue was purified by column-chromatography on silica gel using a mixture of hexane and ethylacetate (3:1) as the eluent to give (37) (5.1 g, 96%).

#### Example 38

- N-(3-(4-Pyrimidyl)phenyl)-4-cyano-2-nitroaniline (38):** To a mixture of (37) (5.5 g, 30 mmol) and 4-chloro-3-nitro-benzonitrile (5.1 g, 30 mmol) in THF (120 ml) was added sodium hydride (2.3 g, 50% suspension in mineral oil). After stirring at room temperature for 2 days, the mixture was poured into water and extracted with  $\text{CH}_2\text{Cl}_2$ . The extract was concentrated under reduced pressure and the residue was triturated with diethyl ether to yield crystalline (38) (9.2 g, 96%).

#### Example 39

*N-(3-(4-pyrimidyl)phenyl)-4-cyano-2-aminoaniline (39):* was synthesized as described in example 37 using (38) (9.2 g, 29 mmol) instead of 4-(3-nitrophenyl)pyrimidine and 600 g catalyst. The reaction gave (39) (8.3g, quant.)

5

#### Example 40

*5-Cyano-1-(3-(4-pyrimidinyl)phenyl)benzimidazole (40):* A mixture of (39) (3.0 g, 10 mmol) and HCO<sub>2</sub>H (20 ml) was stirred at 110°C for 1 hr. The mixture was 10 concentrated in vacuo. The residue was partitioned between a 5% aqueous NaHCO<sub>3</sub> solution and CH<sub>2</sub>Cl<sub>2</sub>. The organic phase was dried over MgSO<sub>4</sub> and the solvent was removed by evaporation. The residue was triturated with ethyl acetate to afford crystalline (40). (2.6g, 85%).

15

#### Example 41

*5-Formyl-1-(3-(4-pyrimidinyl)phenyl)benzimidazole (41a):* Raney Ni (2.2 g) was added to a solution of (40) (3.9 g) in a mixture of HCO<sub>2</sub>H (48 ml) and water (18 ml). The mixture was stirred under argon at 100°C for 0.5 hours. After cooling the mixture was 20 filtered. The filtrate was concentrated partitioned between 1M NaHCO<sub>3</sub> solution and ethyl acetate. The ethyl acetate extract was washed with brine, dried and concentrated under reduced pressure to give (41a) (2.7 g, 69%).

25 *5-Formyl-1-(3-(2-thiazolyl)-phenyl)benzimidazole (41b)* was prepared analogously from (35),

*5-Formyl-1-(3-(1-imidazolyl)-phenyl)benzimidazole (41c)* was prepared analogously from (32b), and

30 *5-Formyl-1-(3-(3-pyridyl)-phenyl)benzimidazole (41d)* was prepared analogously from (32a).

#### Example 42

5-Formyl-1-(3-(4-pyrimidinyl)phenyl)benzimidazole oxime (42a): 41a (2.7 g) was added to a mixture of ethanol (100 ml), NH<sub>2</sub>OH.HCl (1.9 g, 3 equivalents) and triethylamine (1.3 ml, 1 equivalent) and the mixture was stirred at 60°C for one hour. The mixture  
5 was chilled to 0°C and the precipitate was filtered off, washed with water, and dried under reduced pressure to give (42a) (2.2 g, 77%).

5-Formyl-1-(3-(2-thiazolyl)-phenyl)benzimidazole oxime (42b) was prepared analogously from (41b),

10

5-Formyl-1-(3-(1-imidazolyl)-phenyl)benzimidazole oxime (42c) was prepared analogously from (41c), and

15

5-Formyl-1-(3-(3-pyridyl)-phenyl)benzimidazole oxime (42d) was prepared analogously from (41d).

#### Example 43

5-(3-Isoxazolyl)-1-(3-(4-pyrimidinyl)phenyl)benzimidazole (43a):

20 A mixture of 42a (2.1 g) and N-chlorsuccinimide (1.1 g, 1.2 equivalents) in DMF (100 ml) was stirred under argon at 60°C for 0.5 hours. Vinyl bromide (25 ml) was added to the reaction mixture under ice-cooling, and thereafter triethylamine (4.8 ml, 5 equivalents) in 15 ml DMF was added dropwise over one hour. The mixture was stirred at 0°C for 3 hours and at room temperature overnight. The mixture was poured into  
25 water and extracted with ethyl acetate. The organic phase was washed with brine, dried, and concentrated under reduced pressure. The residue was purified by column-chromatography on silica gel using a mixture of CH<sub>2</sub>Cl<sub>2</sub> and methanol (30:1) as the eluent to give 5-(3-isoxazolyl)-1-(3-(4-pyrimidinyl)phenyl)benzimidazole (1.5 g, 64%). M.p. 214-215°C.

30

5-(3-Isoxazolyl)-1-(3-(2-thiazolyl)phenyl)benzimidazole (43b) M.p. 157-158 °C.  
was prepared analogously from (42b)

5-(3-isoxazolyl)-1-(3-(1-imidazolyl)phenyl)benzimidazole (**43c**) was prepared analogously from (**42c**), M.p. 230-234 °C.

5-(3-isoxazolyl)-1-(3-(3-pyridyl)phenyl)benzimidazole (**43d**) was prepared analogously from (**42d**) M.p. 208-210 °C.

#### Example 44

*5-acetyl-1-(3-(3-pyridyl)phenyl)benzimidazole (**44a**):*

- 10    *4-Fluoro-3-nitroacetophenone*: Concentrated sulphuric acid (200 ml) is cooled to 5°C. 4-Fluoroacetophenone (20 ml, 164.76 mmol) is added so that the temperature does not rise above 10°C. The mixture is cooled to 0 - 5°C and potassium nitrate (25 g, 247.14 mmol) is added portionwise over 2 hours keeping the temperature at 0 - 5°C. Following the addition the mixture is stirred at this temperature for 2 hours. The mixture is poured on ice (600 g) and the crude product is filtered off. Column-chromatographic purification on silica-gel using a mixture of ethylacetate and petroleum ether (1:9) as the eluent affords 18.19 g pure 4-fluoro-3-nitroacetophenone (60 %).
- 15    *3-(3-Pyridyl)nitrobenzene* : To 3-bromopyridine (8.53 g, 54 mmol) in ethyleneglycol dimethylether (180 ml) is added 3-nitrophenylboronic acid (10 g, 59.95 mmol), aqueous potassium carbonate (90 ml, 2M) and tetrakis(triphenylphosphine)palladium (0.5 g, 0.43 mmol). The mixture is refluxed gently in a nitrogen atmosphere overnight. The cooled reaction mixture is filtered and water (600 ml) is added to the filtrate. The precipitate is filtered off and washed with water. This crude product is dissolved in hot water (400 ml) with addition of hydrochloric acid (25 ml, 4 M). The mixture is filtered while still hot. The filtrate is cooled in an ice bath and pure 3-(3-pyridyl)-nitrobenzene is precipitated by addition of 12 M NaOH. Yield 9.14 g (85%).
- 25    *3-(3-Pyridyl)aniline* : 3-(3-pyridyl)-nitrobenzene (9.1 g, 45.5 mmol) in ethanol (125 ml) is hydrogenated at ambient pressure for 1.75 hours using Raney Nickel as the catalyst. Filtration of the resulting solution through celite followed by evaporation of solvent quantitatively yields 3-(3-pyridyl)aniline.
- 30

*4-Acetyl-2-nitro-N-(3-(3-pyridyl)phenyl)aniline* : A mixture of 4-Fluoro-3-nitroaceto-phenone (5 g, 27.3 mmol) and 3-(3-pyridyl)aniline (4.62 g, 27.2 mmol) in dry 1-methyl-2-pyrrolidone (10 ml) is stirred at 40-50°C overnight. The resulting solid reaction mixture is suspended in ice water (50 ml) and made alkaline by addition of 1 M

- 5 NaHCO<sub>3</sub>. The product is filtered off, washed with water and dried to yield 7.68 g 4-acetyl-2-nitro-N-(3-(3-pyridyl)phenyl)aniline (85%).

*5-Acetyl-2-(3-(3-pyridyl)phenylamino)aniline* : 4-acetyl-2-nitro-N-(3-(3-pyridyl)-phenyl)-aniline (2 g, 6 mmol) is suspended in a mixture of ethanol (50 ml) and dichloromethane

- 10 (10 ml) and is hydrogenated at ambient pressure using palladium (5% on activated carbon) as the catalyst. Filtration of the resulting solution through celite followed by evaporation of solvent leaves an oil which upon trituration with a mixture of diethylether and petroleumether (1:1) affords 1.46 g pure 5-acetyl-2-(3-(3-pyridyl)phenylamino)aniline (80%).

15

*5-Acetyl-1-(3-(3-pyridyl)phenyl)benzimidazole* : 5-acetyl-2-(3-(3-pyridyl)phenylamino)aniline (5 g, 16.5 mmol) in formic acid (50 ml) is stirred at 90°C for 1.5 hours. The cooled reaction mixture is made alkaline by addition of 12 M NaOH. 5-acetyl-1-(3-(3-pyridyl)phenyl)benzimidazole is filtered off washed with water and 20 dried. Quantitative yield. m.p. 195-97°C.

The following compound was prepared analogously:

*5-Acetyl-1-(3-(4-pyrimidinyl)phenyl)benzimidazole (44b)*.

25

#### Example 45

*5-(5-Isoxazolyl)-1-(3-(4-pyrimidinyl)phenyl)benzimidazole (45a)* was prepared as 30 follows:

*5-(3-dimethylamino-1-oxo-2-propen-1-yl)-1-(3-(4-pyrimidinyl)phenyl)benzimidazole*: (44b) (314 mg) was reacted with DMF-dimethylacetal (1.5 ml) under argon in DMF (3 ml) at 120°C for 5 hours. After cooling to the mixture was poured into water and extracted with ethyl acetate. The organic phase was washed with brine, dried, and 35 concentrated under reduced pressure. The residue was purified by column-chromatography on silica gel using a mixture of CH<sub>2</sub>Cl<sub>2</sub> and methanol (30:1) as the

eluent to give 5-(3-dimethylamino-1-oxo-2-propen-1-yl)-1-(3-(4-pyrimidinyl)phenyl)benzimidazole (320 mg, 87%).

- 5-(5-*Isoxazolyl*)-1-(3-(4-pyrimidinyl)phenyl)benzimidazole : A mixture of 5-(3-dimethylamino-1-oxo-2-propen-1-yl)-1-(3-(4-pyrimidinyl)phenyl)benzimidazole (307 mg) and NH<sub>2</sub>OH.HCl (135 mg, 2.5 equivalents) in methanol (14 ml) was stirred at 80°C for 2 hours. After cooling the mixture was poured into water and extracted with ethyl acetate. The organic phase was washed with brine, dried, and concentrated under reduced pressure. The residue was chromatographed (CH<sub>2</sub>Cl<sub>2</sub>-methanol 40:1 (v/v)) to give 5-(5-isoxazolyl)-1-(3-(4-pyrimidinyl)phenyl)benzimidazole (226 mg, 80%).


The following compounds was prepared analogously:

- 5-(5-isoxazolyl)-1-(3-(2-thiazolyl)phenyl)benzimidazole (**45b**) was prepared  
15 analogously from (**34**), M.p. 186-188 °C.

5-(5-isoxazolyl)-1-(3-(3-pyridyl)phenyl)benzimidazole (**45c**) was prepared analogously from (**44a**). M.p. 218-219 °C. The compounds prepared in the above examples are listed in the following tables 1 and 2.

Table 1

5



Compound No.	Ar	D	A	B	Furan subst. site	m.p. (°C)	Ex.
9c	1-imidazolyl	CH	CH	CH	3	203-204	15
9h	2-(dimethylamino)-5-pyrimidyl	CH	CH	CH	3	183-184	15
9j	2-methyl-1-imidazolyl	CH	CH	CH	3	105-107	15
9k	1-pyrrolyl	CH	CH	CH	3	144-145	15
9l	2-amino-5-pyrimidyl	CH	CH	CH	2	220-222	15
9m	2-(dimethylamino)-5-pyrimidyl	CH	CH	CH	2	170-172	15
9n	1-pyrrolyl	CH	CH	CH	2	137-139	15
9o	1-imidazolyl	CH	CH	CH	2	175-177	15
9p	2-amino-5-pyrimidyl	CH	CH	CH	3	222-223	15
9b	5-pyrimidyl	CH	CH	CH	3	216-218	12


9N	2-methyl-4-thiazolyl	CH	CH	CH	3	136-138	12
9M	1-pyrazolyl	CH	CH	CH	3	170-173	12
9f	2-pyridyl	CH	CH	CH	2	135-136	12
9q	3-furanyl	CH	CH	CH	3	149-150	12
9r	3-(2-pyridyl)-oxadiazol-5-yl	CH	CH	CH	3	183-186	22
9s	3-cyclopropyl-oxadiazol-5-yl	CH	CH	CH	3	144-146	22
9t	2-thiazolyl	CH	CH	CH	3	102-105	19
18b	1-imidazolyl	CH	N	N	3	294-296	15
18c	1-imidazolyl	N	CH	CH	3	170-173	15

5

10

15

Table 2




5

Ar	Isoxazol subst.site	m.p. (°C)	example
4-pyrimidyl	3	214-215	43
3-pyridyl	3	208-210	43
2-thiazolyl	3	157-158	43
1-imidazolyl	3	230-234	43
2-thiazolyl	5	186-188	45
3-pyridyl	5	218-219	45


**We claim:**

1. A compound having the formula:

5



or a pharmaceutically acceptable salt thereof or an oxide thereof  
wherein

10      R<sup>3</sup> is

wherein

A, B and D each is CH, or one or two of A, B and D is N and the others are  
15      CH;

R<sup>11</sup> is phenyl, benzimidazolyl, or monocyclic heteroaryl, all of which may be  
substituted one or more times with substituents selected from alkyl, alkoxy, phenyl,  
halogen, CF<sub>3</sub>, amino, nitro, cyano, acyl, acylamino, phenyl and monocyclic heteroaryl;  
and

20      one of R<sup>6</sup> and R<sup>7</sup> is hydrogen and the other is furanyl or isoxazolyl each of  
which may be substituted one or more times with substituents selected from halogen,  
alkyl, alkoxy and phenyl.

2. A compound of claim 1, which is  
25      1-(3-(1-imidazolyl)phenyl)-5-(3-furanyl)benzimidazole,  
1-(3-(2-methyl-1-imidazolyl)phenyl)-5-(3-furanyl)benzimidazole, or  
1-(3-(5-pyrimidinyl)phenyl)-5-(3-furanyl)benzimidazole,  
or a pharmaceutically acceptable salt thereof or an oxide thereof.

3. A pharmaceutical composition comprising an effective amount of a compound of any of claims 1 to 2, or a pharmaceutically-acceptable addition salt thereof or an oxide thereof, together with at least one pharmaceutically-acceptable carrier or diluent.

5

4. The use of a compound of any of claims 1 to 2 for the preparation of a medicament for the treatment of a disorder or disease of a living animal body, including a human, which disorder or disease is responsive to modulation of the GABA<sub>A</sub> receptor complex of the central nervous system.

10

5. The use of a compound of any of claims 1 to 2 for the preparation of a medicament for the treatment of a disorder or disease of a living animal body, including a human, which disorder or disease is responsive to positive modulation of the GABA<sub>A</sub> receptor complex of the central nervous system.

15

6. The use of a compound of any of claims 1 to 2 for the preparation of a medicament for the treatment of a disorder or disease selected from anxiety, sleep disorders, memory disorders, epilepsy and any other convulsive disorder.

20

7. A method of treating a disorder or disease of a living animal body, including a human, which disorder or disease is responsive to modulation of the GABA<sub>A</sub> receptor complex of the central nervous system comprising administering to such a living animal body, including a human, in need thereof a therapeutically-effective amount of a compound of any of claims 1 to 2.

25

8. The method of claim 7, wherein a disorder or disease responsive to the positive modulation of the GABA<sub>A</sub> receptor complex is treated.

30


9. The method of claim 7, wherein anxiety, sleep disorders, memory disorders, epilepsy or any other convulsive disorder is treated.

10. The method of claim 7, wherein the active ingredient is administered in form of a pharmaceutical composition thereof, in which it is present together with a pharmaceutically-acceptable carrier or diluent.

35


1 / 6

Figure 1:




X is hydrogen or acetyl, A, B, D, and  $\text{R}^{11}$  is as defined in the claims, and Cat. is tetrakis(triphenylphosphine)palladium(0).

Figure 2:



A, B, D, R<sup>11</sup> is as defined in the claims, and Cat. is tetrakis(triphenylphosphine)-palladium(0).


Figure 3:



**A, B, and R<sup>11</sup>** have the meanings set forth in the claims, **Hal** is halogen, **Y** is halogen or carboxy, **R<sup>o</sup>** is alkyl, phenyl, or heteroaryl, and **Cat.** is tetrakis(triphenylphosphine)-palladium(0).

4 / 6


Figure 4:



Hal is halogen, D, A, B, R<sup>11</sup> have the meanings set forth in the claims, and Cat. is tetrakis(triphenyl-phosphine)palladium(0).


5 / 6

Figure 5:



Hal is halogen, D, A, B, and R<sup>11</sup> have the meanings set forth in the claims, R is halogen or furanyl and Cat is tetrakis(triphenylphosphine)palladium(0).

Figure 6:



D, A, B, and R<sup>11</sup> have the meanings set forth in the claims.

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/EP 96/01606

A. CLASSIFICATION OF SUBJECT MATTER				
IPC 6	C07D405/14	A61K31/415	A61K31/42	A61K31/34
				C07D413/14
	C07D417/14	C07D521/00		

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP,A,0 616 807 (NEUROSEARCH AS ;MEIJI SEIKA KAISHA (JP)) 28 September 1994 see page 29 - page 30; claim 1 see page 20; table 1, compounds no. 45a and 57a see page 6, line 30 - page 7, line 31 -----	1-10

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

### \* Special categories of cited documents :

- 'A' document defining the general state of the art which is not considered to be of particular relevance
- 'E' earlier document but published on or after the international filing date
- 'L' document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- 'O' document referring to an oral disclosure, use, exhibition or other means
- 'P' document published prior to the international filing date but later than the priority date claimed

- 'T' later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- 'X' document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- 'Y' document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- '&' document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
9 August 1996	19.08.96
Name and mailing address of the ISA  European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl. Fax (+31-70) 340-3016	Authorized officer  Fink, D

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/EP 96/01606

### Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1.  Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:  
**Although claims 7-10 are directed to a method of treatment of (diagnostic method practised on) the human/animal body the search has been carried out and based on the alleged effects of the compound/composition.**
2.  Claims Nos.: because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3.  Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

### Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1.  As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2.  As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3.  As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4.  No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

#### Remark on Protest

- The additional search fees were accompanied by the applicant's protest.  
 No protest accompanied the payment of additional search fees.

**INTERNATIONAL SEARCH REPORT**Internat'l Application No  
**PCT/EP 96/01606**

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A-0616807	28-09-94	AU-B- 5752194	29-09-94
		CA-A- 2119511	25-09-94
		CN-A- 1099391	01-03-95
		FI-A- 941378	25-09-94
		JP-A- 7002838	06-01-95
		NO-A- 941052	26-09-94
		NZ-A- 260050	26-01-96
		ZA-A- 9402079	24-10-94

This Page is inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record

## BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT OR DRAWING
- BLURED OR ILLEGIBLE TEXT OR DRAWING
- SKEWED/SLANTED IMAGES
- COLORED OR BLACK AND WHITE PHOTOGRAPHS
- GRAY SCALE DOCUMENTS
- LINES OR MARKS ON ORIGINAL DOCUMENT
- REPERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.  
As rescanning documents *will not* correct images  
problems checked, please do not report the  
problems to the IFW Image Problem Mailbox**